Effectiveness of Implantable Cardioverter-Defibrillators for the Primary Prevention of Sudden Cardiac Death in Women With Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Numerous clinical trials have established a role for implantable cardioverter-defibrillators in the prevention of sudden cardiac death in patients with heart failure. However, questions remain that regard the clinical benefit of these therapies in different patient subgroups. Specifically, the role of implantable cardioverter-defibrillators in women with heart failure for the primary prevention of sudden cardiac death has not been well established. Our objective is to determine whether implantable cardioverter-defibrillators reduce mortality in women with advanced heart failure. METHODS: We searched MEDLINE (1950-2008), EMBASE (1988-2008, week 24), the Cochrane Controlled Trials Register (third quarter, 2008), the National Institute of Health ClinicalTrials.gov database, the Food and Drug Administration Web site, and various reports presented at scientific meetings (1994-2007). Eligible studies were randomized controlled trials of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with heart failure that reported all-cause mortality as an outcome for the female population. Of the 2619 reports identified, 5 trials that enroll 934 women were included in the meta-analysis. RESULTS: Pooled data from the 5 trials revealed no statistically significant decrease in all-cause mortality in women with heart failure who receive implantable cardioverter-defibrillators (hazard ratio, 1.01; 95% confidence interval, 0.76-1.33). CONCLUSIONS: Implantable cardioverter-defibrillator therapy for the primary prevention of sudden cardiac death in women does not reduce all-cause mortality. Further studies are needed to investigate the reasons for this ob servation and to define the population of women who may benefit most from implantable cardioverter-defibrillator therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure
Bardy, G. H., Lee, K. L., Mark, D. B., Poole, J. E., Packer, D. L., Boineau, R., Domanski, M., Troutman, C., Anderson, J., Johnson, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043399 · Cited by 6,552
Moss, A. J., Hall, W. J., Cannom, D. S., Daubert, J. P., Higgins, S. L., Klein, H., Levine, J. H., Saksena, S., Waldo, A. L., Wilber, D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352601 · Cited by 4,165
A Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery Disease
Buxton, A. E., Lee, K. L., Fisher, J. D., Josephson, M. E., Prystowsky, E. N., & Hafley, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412503 · Cited by 2,489
Moher, D., Jadad, A. R., Nichol, G., Penman, M., Tugwell, P., & Walsh, S. (1995) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)00031-w · Cited by 1,308
Sudden coronary death in women
Kannel, W. B., Wilson, P. W. F., D’Agostino, R. B., & Cobb, J. (1998) · American Heart Journal · doi:10.1053/hj.1998.v136.90226 · Cited by 417 · cited 1×
“In the Framingham Study, among those who have coronary artery disease, women had only one-fourth the risk of SCD compared with men.(32) Although the underlying mechanism for the difference in mortality rates is not clearly understood, there are some postulated explanations for this observed difference.”
BackgroundGender Difference in the Cycle Length-Dependent QT and Potassium Currents in Rabbits
Liu, X.-K., Katchman, A., Drici, M.-D., Ebert, S. N., Ducic, I., Morad, M., & Woosley, R. L. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37435-x · Cited by 209 · cited 1×
“Data from animal models have demonstrated a smaller repolarizing, slowly delayed, rectifier potassium channel current in female rabbits, which may explain the differences in repolarization in female humans.(35) There are also sex differences in sarcoplasmic reticulum, calcium handling,(36) calcium-channel density,(37)…”
Result
Cited by
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030
Vogel, B., Acevedo, M., Appelman, Y., Bairey Merz, C. N., Chieffo, A., Figtree, G. A., Guerrero, M., Kunadian, V., Lam, C. S. P., Maas, A. H. E. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00684-x · Cited by 1,488
Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association
Mehta, L. S., Beckie, T. M., DeVon, H. A., Grines, C. L., Krumholz, H. M., Johnson, M. N., Lindley, K. J., Vaccarino, V., Wang, T. Y., Watson, K. E., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000351 · Cited by 1,244
“Two metaanalyses have shown contradictory results for all-cause mortality benefit in women with ICDs.(400,401) Additionally, women have a better prognosis after cardiac resynchronization therapy compared with men.”
ResultSex differences in heart failure
Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz835 · Cited by 802
Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy
Fairweather, D., Cooper, L. T., & Blauwet, L. A. (2013) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.07.003 · Cited by 325
Dunbar, S. B., Dougherty, C. M., Sears, S. F., Carroll, D. L., Goldstein, N. E., Mark, D. B., McDaniel, G., Pressler, S. J., Schron, E., Wang, P., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31825d59fd · Cited by 221
Metadata
- Authors
- Ghanbari, H.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2009-09-12
- Volume
- 169
- Issue
- 16
- Pages
- 1500
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2141588258
- Cited by
- 213
- References
- 6
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.